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IGF-I/insulin-like growth factor binding protein 2 (IGFBP-2) coordinately stimulate osteoblast dif-
ferentiation but the mechanisms by which they function have not been determined. AMP-acti-
vated protein kinase (AMPK) is induced during differentiation and AMPK knockout mice have
reduced bonemass. IGF-I modulates AMPK in other cell types; therefore, these studies determined
whether IGF-I/IGFBP-2 stimulate AMPK activation and the mechanism by which AMPK modulates
differentiation. Calvarial osteoblasts and MC-3T3 cells expressed activated AMPK early in differ-
entiation and AMPK inhibitors attenuated differentiation. However, expression of constitutively
activated AMPK inhibited differentiation. To resolve this discrepancywe analyzed the time course
of AMPK induction. AMPK activation was required early in differentiation (day 3–6) but down-
regulation of AMPK after day 9 was also necessary. IGF-I/IGFBP-2 induced AMPK through their
respective receptors and blocking-receptor activation blocked AMPK induction. To determine the
mechanism by which AMPK functioned we analyzed components of the autophagosome. Acti-
vatedAMPKstimulatedULK-1S555phosphorylationaswell asbeclin-1andmicrotubule-associated
protein 1A/1B light-chain phosphatidylethanolamine conjugate (LC3II) induction. Inhibition of
AMPK attenuated these changes and direct inhibition of autophagy inhibited differentiation.
Conversely, expressionofactivatedAMPKwasassociatedwithpersistenceof thesechangesbeyond
day 9 and inhibited differentiation. Blocking AMPK activation after day 9 down-regulated these
autophagosome components and rescued differentiation. This allowed induction of mechanistic
target of rapamycin and AKT, which suppressed autophagy. The results show that early induction
of AMPK in response to IGF-I/IGFBP-2 followed by suppression is required for osteoblast differen-
tiation. AMPK functions through stimulation of autophagy. The findings suggest that these early
catabolic changes are important for determining the energy source for osteoblast respiration and
down-regulation of these components may be required for induction of glycolysis, which is re-
quired during the final anabolic stages of differentiation. (Endocrinology 157: 268–281, 2016)
Insulin-like growth factor I (IGF-I) is a potent stimulantof osteoblast proliferation and gene-knockout studies
have shown that it plays an important role in determining
bone size, mass, and mineralization (1, 2). Recent studies
have shown that a member of the insulin-like growth fac-
tor binding protein (IGFBP) family, IGFBP-2, is also re-
quired for optimal IGF-I-stimulated osteoblast prolifera-
tion and differentiation (3, 4). Deletion of IGFBP-2
resulted in decreased femoral bone volume/total volume
(BV/TV) and reduced femoral length, and it diminished
osteoblastic proliferation and differentiation (5). Rescue
of cells in which IGFBP-2 expression had been deleted
with exogenous addition of IGFBP-2 or a peptide that
contains the active domain of IGFBP-2 restored normal
growth and differentiation (3, 5). The effect of IGFBP-2 is
mediated through a distinct cell surface receptor termed
receptor tyrosine phosphatase  (RPTP), which func-
tions as a tyrosine phosphatase and dephosphorylates
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phosphatase and tensin homolog (PTEN) constitutively
(6). IGFBP-2 binding to RPTP inhibits its phosphatase
activity resulting in increased PTEN tyrosine phosphory-
lation that reduces PTEN-mediated inhibition of AKT (4,
6). However, IGF-I stimulation of AKT activation is re-
quired at a time point that is relatively late in the differ-
entiation cycle; therefore, it is not clear whether there are
signaling events that are stimulated by IGF-I/IGFBP-2
early in the differentiation cycle, and whether these
changes are required for differentiation.
AMP-activatedproteinkinase (AMPK), a cellularmod-
ulator of energy availability, is expressed in low levels in
proliferating preosteoblasts and is activated during osteo-
blast differentiation (7, 8). Activation of AMPK has been
shown to both stimulate (9–11) and inhibit osteoblast
differentiation (12). Some studies have reported that
AMPK activation is induced early during osteoblast dif-
ferentiation and that its induction is required for normal
bone formation invitroand invivo (9–11).AMPK-knock-
outmice have lowbonemass and increased bone turnover
with enhanced resorption (13, 14). Furthermore, follow-
ing ovariectomy the rate of bone loss in AMPK/mice is
retarded compared with controls and both cortical and
trabecularbone thickness is reduced (15).Additional stud-
ies using knockdown of AMPK in cultured osteoblasts
showed that this resulted in attenuated osteogenesis (16).
These studies also showed that AMPK was induced early
in differentiation and that addition of compound C, an
AMPK inhibitor, attenuated differentiation.
In contrast several studies have shown that AMPK in-
hibits AKT, a known stimulant of osteoblast differentia-
tion (17). AMPKphosphorylates TSC-2 S1345,which en-
hances its ability to inhibit mechanistic target of
rapamycin (mTOR)activation (18).TheTORC2complex
that contains activated mTOR mediates AKT S473 acti-
vation (19). Additional studies have shown that AMPK
inhibits IGF-I-stimulated AKT activation (20). Therefore,
it was not clear whether IGFBP-2 and IGF-I could stimu-
late AMPK activation in osteoblasts or why AMPK, a
known inhibitor of AKT activation (which is required for
osteogenic differentiation), would enhance differentia-
tion. Hence, these studies were undertaken to determine
whether IGF-I/IGFBP-2 could regulate AMPK in osteo-
blasts, to determine the downstream signaling events that
occurred in response to AMPK induction and if AMPK
induction was required for IGF-I/IGFBP-2 stimulation of
osteoblast differentiation. Furthermore, we analyzed the
time course of AMPK activation to determine whether
changes in the timing of AMPK activation or its inhibition
could explain conflicting results reported previously,
thereby clarifying the role of AMPK in osteoblast
differentiation.
Materials and Methods
Human IGF-I was a gift from Genentech. Immobilon-P mem-
brane, an anti-pAMPK(T172) antibody and compound C were
purchased from EMDmillipore Corp. -MEM, streptomycin,
and penicillin were purchased from Life Technologies. Antibod-
ies against phospho-AKT (S473), pAMPK(S485), pmTOR
(S2448), phospho-ULK-1 (S555 and S757), LC3I/II, and Be-
clin-1 were purchased from Cell Signaling Technology, Inc. An-
tiosteocalcin and antifibronectin (Fn-3) antibodies were pur-
chased from SantaCruz Biotechnology, Inc. BafilomycinA1 and
PQ401were purchased fromR&D systems. IGFBP-2 antiserum
was prepared as previously described (21). The horseradish per-
oxidase–conjugated mouse antirabbit, goat antimouse, and
mouse antirabbit light chain–specific antibodies were purchased
from Jackson ImmunoResearch Laboratories. All other reagents
were obtained from Sigma unless otherwise stated.
Mice
Generation of the original mixed background strain B6;129-
Igfbp2tm1Jep,whichwe refer to as Igfbp2/mice, hasbeen
described previously (5). The mice were backcrossed onto
C57BL/6J background for 10 generations. Igfbp2/mice were
C57BL/6J controls. All of the experimental studies were per-
formed with male mice. All of the animal studies were reviewed
and approved by the Institutional Animal Care and Use Com-
mittee of University of North Carolina at Chapel Hill.
Cell culture
MC-3T3 E1 clone 4 (CL4) cells were obtained from ATCC.
Cells were cultured in -MEM (glucose 1000 mg/L) containing
10% fetal bovine serum (ThermoFisher Scientific). After con-
fluency, culture mediumwas changed to differentiationmedium
(DM), which contained 10% fetal bovine serum plus 50 ug/mL
ascorbic acid and 4mM -glycerol phosphate. Fresh DM was
applied every 72 hours. In some experiments IGFBP-2 (1 ug/mL)
and/or IGF-I (100 ng/mL) was added to the DM and replaced
every 72 hours unless otherwise stated. Exposure to IGFBP-2 did
not affect cell number, apoptosis, or MAPK activation during
differentiation (4).
Neonatal calvarial osteoblasts were isolated from 3–5-day-
old mice. Cells were obtained from IGFBP-2 (/) mice and
control (/) littermates (3). Briefly, calvaria were digested five
times with collagenase type 2 (250 U/mL) and trypsin (0.05%)
plus EDTA (0.02%) in the PBS. The cells released from digests
2–5 were collected as primary calvarial osteoblasts and main-
tained in -MEM (glucose 1000 mg/L) supplemented with 10%
fetal bovine serum and nonessential amino acids.
Construction of cDNAs and establishment of
MC3T3 cells expressing wild-type IGFBP-2, AMPK
(1–312) T172D, and -galactosidase (LacZ)
Thepreparationof the constructs that contained IGFBP-2 (4),
AMPK (1–312) T172D, and LacZ (20) have been described pre-
viously. That these constructs contained the correct sequences
was verified by DNA sequencing. 293FT cells (Life Technolo-
gies) were prepared for generation of virus stocks and CL4 ex-
pressing IGFBP-2, AMPK T172D, and LacZ were established
using procedures that have been described previously (22).
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Construction of cDNAs and establishment of
IGFBP-2 Si and LacZ Si cells
Based on Life Technologies’ website design tools, a sequence
containing 21 oligonucleotides (GGAAAGAGACCAACACT-
GAGC) was used to construct the shRNA template plasmid to
inhibit the translation of mouse IGFBP-2 mRNA. The oligonu-
cleotides were synthesized by Nucleic Acids Core Facility at the
University of North Carolina annealed and ligated into
BLOCK-iT U6 RNAi Entry Vector (Cat No. K4945-00, Life
Technologies) following the manufacturer’s instructions. The
complete sequence was verified by DNA sequencing. The ex-
pression vector was generated using the Gateway LR recombi-
nation reaction between the Entry Vector and BLOCK-iT Len-
tiviral RNAi Gateway Vector (Cat No. K4943-00, Life
Technologies). A sequence targeting LacZwas used as a control.
After confirmation of the sequence, plasmid DNAwas prepared
using a Plasmid Midi Kit (Promega). 293FT cells (Life Technol-
ogies) were transfected and used to prepare for generation of
virus stocks. CL4 cells expressing small hairpin RNA sequence
targeting IGFBP-2 (IGFBP-2 Si) and corresponding control CL4
expressing small hairpin RNA sequence targeting LacZ (Ctrl Si)
were established using procedures described previously (22)
Immunoblotting
The cell monolayers were lysed in a modified radioimmuno-
precipitation assay buffer as previously described (22). Immu-
noblotting was performed as previously described (22) using a
dilution 1:1000 for anti- pAKT (Ser473), pAMPK (T172, S485),
pmTOR (S2448), pULK (S555 and S757), LC3I/II, Beclin-1 and
-actin antibodies. A dilution of 1:150 was used for antiosteo-
calcin and a dilution 1:10000 for anti-IGFBP-2. The proteins
were visualized using enhanced chemiluminescence (Thermo-
Fisher Scientific). Total cellular protein in the lysates was deter-
mined using bicinchoninic acid assay (ThermoFisher Scientific).
Alizarin Red staining
Cellswerewashedwith PBS twice before theywere fixedwith
10% formalin. After 10minutes’ fixation, 1%Alizarin Red (pH
4.2) was applied and incubated for another 10 minutes before it
was removed. Cells were washed with ddH2O twice and dried.
Images were captured using Leica M420 Microscope. The time
courseof the change inAlizarin red stainingaswell as osteocalcin
expression during the course of differentiation inMC3T3 cells is
shown in Supplemental Table 1.
Statistical analysis
Densitometry results are expressed as the mean  SD. All
experiments were replicated at least three times to assure repro-
ducibility. The results were analyzed for statistically significant
differences using Student t test or ANOVA followed by the Bon-
ferroni multiple comparison post-hoc test. Statistical signifi-
cance was set at P  .05.
Results
Biphasic regulation of AMPK is required for
optimal osteoblast differentiation
To determine whether AMPKwas induced early in dif-
ferentiation MC-3T3 cells were exposed to beta glycerol
phosphate, and ascorbic acid in 10% fetal bovine serum
and the abundance of AMPK phospho (T172) (located in
the activation loop) assessed by direct immunoblotting.
PhosphoAMPK (T172) increased2.90.4-fold (P .01)
between days 1 and 3 of differentiation (Figure 1A). This
was followed by a significant decrease (70.6 0.6%; P
.01) between days 9 and 15 whereas there was no signif-
icant change in AMPK protein. To assess the significance
of this change for osteoblast differentiation, compoundC,
anAMPK inhibitor, was added early in the differentiation
cycle and at later time points. The addition of this AMPK
inhibitor on day 0 or 3 resulted in attenuation of differ-
entiation (inhibition of alizarin red staining) whereas ad-
ditiononday9or later hadnoeffect (Figure1B). Similarly,
osteocalcin expression was reduced 73.1  6.4% (P 
.01) in the day-0-treated cultures compared with control
(Figure 1C). The results suggest that induction of AMPK
early in the differentiation cycle is required and that prior
studies that reported AMPK inhibited differentiation
might be explained by persistent activation of AMPK at
later time points (12). To test this hypothesis we repeated
the experiment but metformin was added to stimulate
AMPK between days 9 and 18. As shown in Figure 1D,
addition of metformin on days 9 and 12 attenuated dif-
ferentiation whereas addition on day 18 had no effect.
Measurement of osteocalcin expression confirmed this re-
sult (Figure 1E). To confirm that this change was due to
AMPK activation we used cells that expressed an AMPK
mutant that was constitutively activated (T172D). Ex-
pression of thismutant resulted in near-complete suppres-
sion of osteoblast differentiation as assessed both by Aliz-
arin Red staining or osteocalcin expression (Figure 2, A
and B). Given that activated AMPK was expressed at rel-
atively high levels through day 9 in nontransfected cells
but then decreased (Figure 1A), we determined the effect
of adding compoundCon day 9 to cells that expressed the
constitutively active mutant. Addition of compound C on
days 9 and 12 rescued differentiation but addition on day
15 or 18 had no effect (Figure 2C). Analysis of osteocalcin
expression showed that it was increased 4.1  0.7-fold
(P  .01) in the cultures exposed to compound C on day
9 compared with control (Figure 2D). These results dem-
onstrate that during the midphase of differentiation sup-
pression of AMPK activity is required to complete the
differentiation cycle.
IGF-I and IGFBP-2 stimulate AMPK activation at the
early stage of differentiation
To determinewhether IGF-I and IGFBP-2 played a reg-
ulatory role inAMPK inductionweused cells overexpress-
ing IGFBP-2. IGFBP-2 overexpression stimulated AMPK
(phosphoT172) on days 3–9 and the levels on day 6 and 9
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Figure 1. Biphasic regulation of AMPK activation is required for osteoblast differentiation. A, Cell lysates from MC-3T3 cells following exposure to
DM for the indicated number of days were prepared and immunoblotted with an anti-pAMPK (T172) antibody as described in Materials and
Methods. -actin was immunoblotted as a loading control. Each bar is the ratio of the scan value of the pT172AMPK band divided by the AMPK
band. B and D, MC-3T3 cells were stained by Alizarin Red on day 21 after DM alone (control) or DM plus compound C (1uM) (B) or metformin
(0.5mM) (D), which had been added on the indicated day. C and E, Cell lysates were obtained from MC-3T3 cells on day 21 following DM
exposure in the absence or presence of compound C (1uM) (C) or metformin (0.5mM) (E) that had been added on the indicated day. They were
immunoblotted with antiosteocalcin or anti--actin. Each bar is the ratio of the scan value of the osteocalcin band divided by the -actin band.
**, P  .01 and ***, P  .001 indicate significant differences between two treatments.
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were 2.2  0.1 (P  .01) and 1.4  0.1 (P  .05) -fold
greater than control cultures (Figure 3A). To confirm the
role of IGFBP-2, SiRNA was used. Cultures in which
IGFBP-2 was significantly decreased showed a significant
reduction in AMPK T172 phosphorylation between days
3–9 compared with control cultures (56  3%, P  .01;
70  5%, P  .01; and 73  17%, P  .05 decreases on
days 3,6, and 9, respectively) (Figure 3B). Activation of
AMPK could be restored by adding
IGF-I or IGFBP-2 to the Si RNA
treated cultures (Figure 3C). Given
that these results showed that
IGFBP-2 stimulated AMPK activa-
tion wemeasured IGFBP-2 secretion
in nontransfected MC-3T3 cells
early in differentiation. IGFBP-2was
increased3.80.6 (P .01) -foldon
day 3. This was sustained on day 6
but decreased significantly on day 9
(62 7% reductionn; P .01) (Fig-
ure3D).Todeterminewhether IGF-I
and IGFBP-2 were stimulating
AMPK though binding to their re-
spective receptors, PQ401, an IGF-I
receptor tyrosine kinase inhibitor,
and an antifibronectin-3 antibody
that inhibits IGFBP-2 binding to
RPTP (4, 6)were used. As shown in
Figure 3, C and E, these inhibitors
attenuated the ability of IGF-I
and IGFBP-2 to stimulate AMPK
(eg, 74  7%, P  .01; 67  7%,
P  .05, reductions, respectively)
thereby confirming that activation of
both receptors was required.
Activation of AMPK stimulates
autophagy, which is required
for osteoblast differentiation
Recent reports have suggested
that stimulation of autophagy is nec-
essary for early osteoblast differen-
tiation. Given that AMPK directly
phosphorylates unc-51 like au-
tophagy activating kinase-1(ULK-
1), thereby stimulating ULK-1 acti-
vation and this is required to
assemble essential components of
the autophagosome, we investigated
the possibility that the transient in-
duction of AMPK early in differen-
tiation was leading to stimulation of
autophagy. Characterization of the
time course of these changes in nontransfected MC-3T3
cells showed that phosphorylation of ULK-1 S555 (a
known AMPK phosphorylation site) was increased 2.7
0.5-fold (P  .05) on day 2 and 2.4  0.2-fold (P  .01)
on day 3 in parallel with AMPK activation (Figure 4A).
Consistent with the changes in AMPK activation ULK-1
S555 phosphorylation on day 9 was markedly attenuated
Figure 2. Constitutively activated AMPK impaires osteoblast differentiation. A, LacZ- or AMPK
T172D-overexpressing cells were stained by Alizarin Red on the indicated day after DM exposure.
B, Lysates obtained from the cells expressing LacZ or AMPK T172D on the indicated day
following DM exposure were immunoblotted with antiosteocalcin or -actin. C, AMPK T172D-
overexpressing cells were stained with Alizarin Red on 21 days after DM exposure in the absence
(control) or the presence of compound C (1uM) that was added on the indicated day. D, Lysates
obtained from cells overexpressing AMPK T172D after 21 days of DM exposure in the absence or
in the presence of compound C (1uM) added on the indicated day were immunoblotted with
antiosteocalcin or -actin. Each bar is the ratio of the scan value of the osteocalcin band divided
by the -actin band. **, P  .01 indicates significant differences between two treatments.
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(72 9%; P .01, decrease compared with day 3). Sim-
ilarly, microtubule-associated protein 1A/1B light-chain
phosphatidylethanolamine conjugate (LC3I/II) and be-
clin-1, important components of the autophagosome,
showed increased expression on days 2–6 (eg, 3.0 0.5-
fold, P .01, and 4.8 0.9-fold, P .001 on day 2) that
was attenuatedonday9.Enhanced expressionof IGFBP-2
accelerated the time course of the increase inULK-1 serine
555 phosphorylation and beclin-1 and LC3I/II expression
(3.1  0.5, P  .05; 7.8  0.5, P  .001; 4.9  0.9 P 
Figure 3. Activation of AMPK at the early stage of differentiation is positively regulated by IGFBP-2 and requires IGF-I receptor activation. A, Cell
lysates obtained from LacZ- or IGFBP-2-overexpressing cells on indicated day after exposure to DM were immunoblotted with anti-pAMPK (T172),
IGFBP-2 or -actin. B, Lysates from MC-3T3 cells expressing shRNA sequence targeting LacZ (Ctrl Si) or IGFBP-2 (IGFBP-2 Si) obtained on the
indicated day after DM exposure were immunoblotted with anti-pAMPK (T172), IGFBP-2, or -actin. C, Lysates from MC-3T3 cells expressing
shRNA sequence targeting IGFBP-2 (IGFBP-2 Si) following a 3-day DM exposure in the absence or the presence of IGF-I (100 ng/mL) alone or
IGFBP-2 (1 ug/mL) alone or both or IGF-I and IGFBP-2 plus antifibronectin antibody-3 (anti-Fn) (500 ng/mL) were immunoblotted with anti-pAMPK
(T172) or anti-AMPK. Each bar is the ratio of the scan value of the pT172AMPK band divided by the AMPK band. **, P  .01 indicates significant
differences between two treatments. D, Lysates from MC-3T3 cells obtained on the indicated day after DM exposure were immunoblotted with
anti-IGFBP-2. E, Lysates from IGFBP-2 overexpressing cells obtained on day 3 after DM exposure in the absence or the presence of PQ401 (25uM)
were immunoblotted with anti-pAMPK (T172) or anti-AMPK.
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Figure 4. Activation of autophagy at the early stage of differentiation is required for optimal osteoblast differentiation. A, Lysates from MC-3T3
cells obtained following exposure to DM for the indicated days were immunoblotted with anti-pAMPK (T172), pULK (S555), LC3 I/II, Beclin-1, or
-actin. B and D, Lysates from LacZ- (Ctrl) or IGFBP-2-overexpressing cells (B) or from MC-3T3 cells expressing shRNA sequence targeting LacZ (Ctrl
Si) or IGFBP-2 (IGFBP-2 Si) (D) obtained on indicated day after DM exposure were immunoblotted with an anti-pULK (S555), LC3 I/II, Beclin-1, or
-actin antibody. C, Lysates from MC-3T3 cells after 3 days of DM exposure in the absence or the presence of compound C (CC) (1uM) were
immunoblotted with an anti-pAMPK (T172), pULK (S555), LC3 I/II, Beclin-1, or -actin. E, Lysates from MT-3T3 cells expressing the shRNA-
targeting IGFBP-2 (IGFBP-2 Si) after 3 days of DM exposure in the absence or the presence of metformin (Met) (0.5mM) were immunoblotted with
an anti-pAMPK (T172), pULK (S555), LC3 I/II, Beclin-1, or -actin. F, Lysates from MC-3T3 cells after 3 days of DM exposure in the absence or the
presence of IGF-I (100 ng/mL) or IGFBP-2 (1 ug/mL) or both were immunoblotted with an anti-pULK (S555) or -actin. G, Lysates obtained from
cells overexpressing AMPK T172D after 9 or 12 days of DM exposure in the absence or in the presence of compound C (1uM) were
immunoblotted with an anti-pULK (S555), LC3 I/II, Beclin-1, or -actin. H, MC-3T3 cells were stained by Alizarin Red on day 21 after DM alone
(Ctrl) or DM plus bafilomycin-1A (2nM) added on the indicated day.
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.01 -fold increases on day 1 compared with control) (Fig-
ure 4B). The addition of compound C markedly attenu-
ated the changes in these components that occurredonday
3 (Figure 4C). IGFBP-2 knockdown attenuated ULK-1
phosphorylation (54  6% reduction; P  .05 on day 3)
and beclin-1 and LC3I/II induction (53 2 and 59 3%
reductions; P  .01, on day 6) (Figure 4D). In contrast,
metformin stimulated ULK-1 phosphorylation, LC3I/II,
and beclin-1 on day 3 even in the absence of IGFBP-2
(Figure 4E). As for AMPK induction, both IGF-I and
IGFBP-2 stimulated ULK-1 S555 on days 1–3 (3.4 0.4,
P  .01; and 4.4  0.8, P  .01, -fold increases, respec-
tively) (Figure 4F). The addition of compound C on day 9
or12,which rescueddifferentiation in theAMPK-T172D-
overexpressing cells, significantly suppressedULK-1 S555
phosphorylation, beclin-1, and LC3I/II expression ( 48
2%, P .01; 58 8%, P .01, and 60 2%, P .05,
decreases, respectively) (Figure 4G). To determine
whether these changes were relevant to autophagy we
measured differentiation in response to the addition of
bafilomycin, an autophagy inhibitor. The addition of ba-
filomycin between days 0 and 6 inhibited osteoblast dif-
ferentiationwhereas additiononday12hadno effect (Fig-
ure 4H). These results clearly demonstrate that autophagy
is required but only early in the differentiation cycle con-
comitantly with AMPK activation. Taken together, the
findings strongly suggest that IGF-I/IGFBP-2 induce
AMPK early in differentiation and that this is required to
activate autophagybut thatAMPKactivationmust alsobe
attenuated after day 9 for differentiation to proceed.
Activation of AKT and mTOR are responsible for
suppression of AMPK at the late stage of
differentiation
To understand the underlying mechanism for suppres-
sion of AMPK activation and autophagy in the middle of
the differentiation cycle, we focused on the changes that
occurred between days 6 and 15. Late activation of
mTOR/AKT has been observed in osteogenic differentia-
tion of human meschymal stem cells (16); therefore, the
changes in phospho mTOR (S2448) and phospho AKT
(S473) were determined. The results show that activation
of mTOR and AKT increased substantially between days
6 and 15 (Figure 5A). Phosphorylation of AMPK S485,
which ismediatedbyAKTandnegatively regulatesAMPK
activity (20), was also increased. Enhanced IGFBP-2 ex-
pressionwas accompanied by increased AKT S473 (2.0
0.2-fold increase; P  .01 on day 15) and AMPK S485
phosphorylation (2.1 0.2-fold increase; P .01 on day
9) (Figure 5B). Similarly, IGFBP-2 overexpression stimu-
lated mTOR activation (3.5  0.4-fold; P  .001 on day
9) compared with control cultures. This led to enhanced
Figure 5. Activation AMPK is suppressed at the middle and late stage of differentiation via activation of mTOR and AKT. A, Cell lysates from MC-
3T3 cells following exposure to DM for the indicated days were immunoblotted with an anti-pmTOR (S2448), pAKT (S473), pAMPK (S485), or -
actin. B and C, Lysates from LacZ- (Ctrl) or IGFBP-2-overexpressing cells (B) or from MC-3T3 cells expressing AMPK T172D (C) obtained on the
indicated day after DM exposure were immunoblotted with anti-pmTOR (S2448), pULK (S757), pAKT (S473), pAMPK (S485), or AMPK. D, Lysates
from MC-3T3 cells following exposure to DM for 9 days in the presence of or absence of AKT inhibitor (AKT in) (500nM) were immunoblotted
with an anti-pAKT (S473), pAMPK (S485, T172), or AMPK. E, Lysates from MC-3T3 cells following exposure to DM for 9 days in the presence of or
absence of rapamycin (500nM) were immunoblotted with an anti-pmTOR (S2448), pULK (S757, S555), or -actin.
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phosphorylation of ULK-1 S757, a known mTOR phos-
phorylation site (3.2  0.8-fold increase on day 9; P 
.001) (Figure 5B). This change down-regulates ULK-1 ac-
tivity and inhibits autophagy (23). In contrast, overex-
pression of constitutively active AMPK (T172D) pre-
vented the increases in mTOR Ser2448 and AKT S473
phosphorylation on days 9 and 15; consequently, there
was no increase inULK-1 S757 orAMPKS485 phosphor-
ylation (Figure 5C). To confirm that the change in AMPK
S485 led to a decrease in AMPK activation we used an
AKT inhibitor. This reduced S485 phsophorylation by 69
 5% (P .01) and increased T172 phsophorylation 2.3
 0.4-fold, (P .05) (Figure 5D). Similarly, the addition
of anmTORinhibitor reducedULK-1phsophorylationby
65  6% (P  .01), which was associated with a 2.4 
0.3-fold (P  .01) increase in ULK-1 S555 (Figure 5E).
Therefore, our results show that activation of AKT sig-
naling is responsible for down-regulation of AMPK acti-
vation andmTORdown-regulates ULK-1 during themid-
dle and late phases of differentiation.
Biphasic regulation of AMPK and autophagy is
required for calvarial osteoblast differentiation
To determine the physiologic relevance of these find-
ings for normal osteoblast differentiation primary mouse
calvarial osteoblasts, isolated from control and IGFBP-
2/ mice were subjected to similar treatments. Analysis
of AMPK T172 expression in the absence of IGFBP-2
showed that it was significantly suppressed on days 3–9
(Figure 6A). The addition of IGFBP-2 to the/ cultures
resulted in significant stimulation of AMPK T172 phos-
phorylation (eg, 1.5 0.2, P .05; 7.6 0.8, P .001;
and 8.3 1.2, P .01, fold increases on days 3, 6, and 9
compared with control). This was accompanied by cor-
responding changes in ULK-1 phosphorylation (eg, 1.3
0.1-fold increase on day 3, P .05; and 2.8 0.2-fold on
day 6, P .05) (Figure 6B). As for the MC-3T3 cells, the
loss of expression of IGFBP-2 resulted in attenuated
ULK-1 S555 phosphorylation on days 3 and 6 and there
was a decrease in beclin-1and LC3I/II abundance (Figure
6C). Consistently, addition of bafilomycin at the early
stage, such as on day 0 or day 3, significantly impaired
wild-type (WT) osteoblast differentiation (Figure 6D). To
determine whether AMPK was required for differentia-
tion, compound C was added to osteoblast cultures de-
rived from WT mice between days 0 and 12 and Alizarin
Red staining determined. The addition of compoundC on
day 0 or 3 attenuated differentiation whereas addition on
days 9 and 12 had no effect (Figure 6E). These findings
were confirmed when osteocalcin expression was deter-
mined (Figure 6F). To assess the importance of attenua-
tion AMPK stimulation later in the differentiation cycle
metformin was added on days 9–18. As shown in Figure
6G the addition of metformin on day 9 or 12 resulted in
significant inhibition of differentiation whereas addition
at later times had no effect. When osteocalcin expression
was determined this finding was confirmed (Figure 6H).
Theadditionofmetforminonday9, 12, and15 stimulated
AMPK T172 phosphorylation (Figure 6I). The results
clearly demonstrate that induction of AMPK early in the
differentiation cycle in primary osteoblasts is required for
differentiation. IGFBP-2 stimulates these changes and at-
tenuation of AMPK activation between days 9 and 15 is
also required.
Discussion
Our results demonstrate that the requirement for AMPK
activation and its role in stimulating osteoblast differen-
tiation is biphasic. Specifically, induction of AMPK acti-
vation early in the differentiation cycle is required for dif-
ferentiation to proceed but failure to down-regulate
AMPKafter day 9 results in attenuation of differentiation.
That AMPK induction is required is supported by the fact
that expression of osteocalcin and Alizarin Red staining
were inhibited when AMPK activation was suppressed
between days 0 and 6. This requirement was clearly con-
text specific and time limited given that addition of an
AMPK inhibitor at later time points had no effect. The
necessity for down-regulating AMPK activation after day
9 was confirmed using a different strategy. Specifically,
overexpression of a constitutively activated form of
AMPK inhibited differentiation but the addition of an
AMPK inhibitor between days 9 and 12 resulted in com-
plete restoration of the osteoblast differentiation. This
strongly suggests that AMPK activity must be down-reg-
ulated at later stages in order for differentiation to
proceed.
Prior studies reported that activation of AMPK is re-
quired for osteoblast differentiation in vitro (9–11). Both
MC-3T3 and primary murine osteoblasts showed en-
hanced differentiation in response tometformin or 5-ami-
noimidazole-4-carboxamide ribonucleotide (AICAR),
agents that induce AMPK (9–11, 24–26), but the in-
creases in AMPK were transient (eg, 1–3 h) making it dif-
ficult to conclude that AMPK induced a change in differ-
entiation that occurred over 14 days. Other studies
showed that an 8–14-day exposure to AICAR increased
osteocalcin and Runx2 expression but did not document
that this enhancedAMPKactivity throughout this interval
(11, 26). Shah et al (9) reported metformin stimulated
mineralized nodule formation in primary rat osteoblasts
after 17 days and that this was inhibited with compound
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C but AMPK activation was not measured. Therefore,
noneof these reports demonstrated sustainedactivationof
AMPK during the course of differentiation.
Three studies analyzed the effect of altering AMPK ac-
tivity in vivo. Shah et al (9) reported thatAMPK-knockout
mice had reduced trabecular number andBV/TVaswell as
trabecular and cortical thickness. Quinn et al (25)
knocked out the AMPK beta 2 subunit which led to re-
duced BV/TV, trabecular number, and bone mineral den-
sity (BMD). However, treatment of normal mice with
Figure 6. Biphasic regulation of AMPK is required for calvarial osteoblast differentiation. A and B, Calvarial osteoblasts isolated from IGFBP-2/
WT or IGFBP-2/ mice were exposed to differentiation medium (DM) for indicated number of days. A, Lysates were immunoblotted with anti-
pAMPK(T172) or -actin. B, Calvarial osteoblasts isolated from IGFBP-2/ mice were exposed to DM for indicated days in the absence or the
presence of IGFBP-2 (1 ug/mL). Lysates were immunoblotted with anti-pAMPK (T172), pULK (S555), or AMPK. C, Lysates were immunoblotted
with an anti-pULK (S555), LC3 I/II, Beclin-1 or -actin. D, E, and G, Cells were stained by Alizarin Red on day 21 after DM alone (control) or DM
plus bafilomycin A1 (2nM) (D), compound C (1uM) (E), or metformin (0.5 mM) (G) that had been added on the indicated day. F and H, Cell lysates
from the same treatments as panel E (F) or G (H) were immunoblotted with an antiosteocalcin or -actin antibody. I, Lysates from cells that had
been exposed to DM for indicated number of days in the absence or presence of metformin (0.5mM) for 2 hours were immunoblotted with anti-
pAMPK (T172) or AMPK.
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AICAR also resulted in decreased BV/TV, trabecular
thickness and BMD. This was attributed to increased os-
teoclast formation in response to AMPK activation but
whether prolonged exposure AICAR also inhibited osteo-
blast differentiation was not analyzed. In contrast, Kasai
et al (12) showed that a transient increase in AMPK ex-
pression inhibited primary mouse osteoblast differentia-
tion. Unlike the other reports these investigators showed
that AMPK was induced at several points during the 18-
day treatment period. In an attempt to resolve these dif-
ferences Pantovik et al (16) showed that dexamethasone
stimulated an increase in AMPK and suppressed mTOR
on days 1 and 3 in dental pulp mesenchymal stem cells.
Knockdown of AMPK at day 1 inhibited differentiation
but knockdown of mTOR reduced alkaline phosphatase
induction at day 7. They concluded that AMPK and au-
tophagy were activated early in differentiation but they
didnot address the significanceof changes in eitherAMPK
or autophagy that occurred after day 5.
Our study significantly extends these observations by
confirming that AMPK induction is required early during
differentiation and that IGF-I and IGFBP-2 stimulate
AMPK.More importantly,we delineated the downstream
events that occur following AMPK activation that lead to
osteoblast differentiation (Figure 7). Although prior stud-
ies have suggested that direct phosphorylation of AKT or
induction of DLX5-dependent Runx2 expression (26) are
mechanisms by which AMPK stimulates differentiation,
our finding that AMPK stimulates ULK-1 phosphoryla-
tion at the same time that autophagy is being initiated
provides a mechanism for coordinating changes in energy
metabolism and autophagy. Prior reports have suggested
that induction of autophagy is required for osteoblast dif-
ferentiation. Pantovik et al (16) showed that activation of
AMPK on days 1–5 was accompanied by an increase in
LC3I/II and beclin-1 and that the autophagy inhibitor,
bafilomycin, inhibited alkaline phosphatase induction.
Changet al (27)demonstrated inbonemarrowosteoblasts
deletion of p62, a protein that transports cargo to the
autophagosome, resulted in inhibition of differentiation,
whereas induction of p62 resulted in full differentiation.
Two studies in mice have confirmed the importance of
autophagy for normal bone formation. Liu et al (14) dem-
onstrated that deletion of an essential component of the
autophagosome complex (FIP 200) led to multiple au-
tophagy defects, deficient mineralization, decreased BV/
TV, trabecular number, and cortical thickness. Using os-
teoblasts isolated from these mice they confirmed that
there was a defect in differentiation. Nollet et al (13)
showed that knockdown of ATG 5, a component of the
autophagosome resulted in decreased bone volume and
mineralization aswell as an increase in osteoclast number.
BV/TV, trabecular width, and num-
ber were also reduced significantly.
Taken together, these findings
strongly support the conclusion that
autophagy is required for normal
bone cell differentiation.
Our study adds to these findings
by demonstrating induction of au-
tophagy is required early in differen-
tiation and that IGF-I and IGFBP-2
stimulate increases in important
components of the autophagosome
(Figure 7). To determine the signifi-
cance of AMPK induction for au-
tophagy, we analyzed the down-
stream signaling target ULK-1 given
that this kinase is a principal regula-
tor of the initial phase of autopha-
gosome formation and AMPK has
been shown to activate ULK-1
through S555 phosphorylation. Our
results also show that phosphoryla-
tion of ULK-1 S555 is increased at
the time when beclin-1 and LC3I/II,
essential components of the au-
tophagosome, are also increased and
Figure 7. Biphasic regulation of AMPK and autophagy is required for osteoblast differentiation.
At the early stage of differentiation, IGF-I and IGFBP-2 stimulate AMPK activation via IGF-I
receptor and RPTP dependent pathways, respectively, resulting in activation of autophagy. This
early activation of AMPK and autophagy is required for optimal osteoblast differentiation. At the
late stage of differentiation, IGF-I and IGFBP-2 stimulate RPTP oligomerization and inactivation,
leading to inactivation of PTEN and activation of AKT (S473 phosphorylation). Activation of AKT
stimulates AMPK S485 phosphorylation, leading to the suppression of AMPK activation
(reduction of T172 phosphorylation) and the termination of autophagy. Activation of mTOR at
this stage further suppresses autophagy via activation of ULK S757. These signaling events at the
late stage are also essential for optimal osteoblast differentiation.
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that inhibition of AMPK decreased ULK-1 S555 phos-
phorylation and inhibited LC3I/II and beclin-1 induction.
Studies in other cell types have demonstrated that AMPK
stimulates autophagy through direct phosphorylation of
ULK-1 S555 and mutagenesis of that serine inhibits au-
tophagy (28). Models of nutrient deprivation or other
stresses that are known to activate AMPK result in direct
phosphorylation ofULK-1 S555 and this enhancesULK-1
mediated stimulation of autophagosome formation (23,
29, 30). Given that addition of compoundCbetween days
0and3completely attenuatedosteoblastdifferentiationas
well as the induction of autophagosome components and
direct inhibition of autophagy using bafilomycin added at
the same time points inhibited differentiation, we con-
clude that AMPK phosphorylation of ULK-1 S555 is in-
ducing autophagy and this is required for differentiation.
Importantly, we demonstrated that IGF-I/IGFBP-2 regu-
lated beclin-1 and LC3I/II expression, changes that led to
autophagosome formation (29).
Our results also emphasize the importance of AMPK
down-regulation for termination of autophagy and that
this change is required for differentiation. The decrease in
AMPK activation after day 9 in nontransfected cells was
associatedwith an increase inAKTactivation,which stim-
ulatedAMPKS485 phosphorylation a change that down-
regulates AMPK activity (20, 31). Concomitantly, mTOR
phosphorylated ULK-1 on S757 and this inhibits ULK-1
activity. This has been shown to be the mechanism by
which mTOR down-regulates autophagy (27, 32). Our
finding that expression of constitutively activated AMPK
resulted in persistent ULK-1 S555 phosphorylation, be-
clin-1 induction, and suppression of ULK-1 757 phos-
phorylation beyond day 9, whereas compoundC addition
inhibited these changes and rescued differentiation, pro-
vides further evidence of the importance of AMPK down-
regulation in the later stages of differentiation. AMPK
phosphorylates TSC-2 S1345, which enables it to inhibit
mTOR activation (18). Our results show that AMPK
down-regulation after day 9 permits induction of mTOR
and AKT activation and that AKT supresses AMPK ac-
tivity through S485 phosphorylation. However, the event
that catalyzes the change from IGF-I/IGFBP-2 stimulation
of AMPK activity early in differentiation to their subse-
quent stimulation of AKT and mTOR leading to AMPK
andULK-1inhibitionwas not defined.Other investigators
have shown that induction of the TORC2 complex,which
contains activatedmTORat day 9 is critical for osteoblast
differentiation and that this is involved in the switch in
energy metabolism from oxidative phosphorylation to
glycolysis (33). In that report the changes were mediated
by WNT-5 an important osteoblast trophic factor. Given
that AMPK is a major stimulant of oxidative phosphor-
ylation and it inhibits glycolysis, our observation that
there is a decline in AMPK activity and increased mTOR
andAKT activation at the time at which TORC2 has been
reported to be increased suggests that down-regulation of
AMPK activation is part of a coordinated series of events
that is necessary to the switch from oxidative phosphor-
ylation to glycolysis a metabolic reprograming response
that has been shown to be important for osteoblast dif-
ferentiation (33, 34).
Our findings also highlight the importance of coordi-
nate stimulationbyboth IGF-I and IGFBP-2 for osteoblast
differentiation. Several investigators have shown that
IGF-I is an important anabolic factor for bone and that
deletion of the IGF-I receptor results in major attenuation
of late-stage differentiation events such as calcium incor-
poration and extracellular matrix synthesis (1, 2, 35, 36).
IGF-I knockout mice exhibit decreased BV/TV and de-
creased BMD (1, 2, 37). Similarly, IGFBP-2 deletion re-
sults in a phenotype in whichmales and estrogen deficient
females have attenuated bone formation, decreased tra-
becular number, and decreased BV/TV (5) (38). Exposure
to both IGF-I and IGFBP-2 is required for stimulation of
osteoblast differentiation and the two distinct signaling
pathways that are stimulated by each protein through its
distinct receptor interact to enhance AKT activation,
which is required for progression through the differenti-
ation cycle (4). These studies extend those observations to
show that inhibition of IGF-I receptor activation or inhi-
bition of IGFBP-2 induced RPTP inactivation results in
attenuation of AMPK induction and ULK-1 S555 phos-
phorylation. Therefore, it is likely that IGF-I and IGFBP-2
are inducing autophagy through this mechanism.
The basis for understanding why anabolic factors such
as IGF-I/IGFBP-2 induce AMPK and autophagy and the
linkage between these events and the progression of os-
teoblast differentiation to the anabolic phase was not ad-
dressed in the studies. However, the finding that a tem-
poral orderof eventsdescribedhereinwherebyAMPKand
autophagy are induced early and then have to be sup-
pressed later in differentiation provides a new perspective
for analyzing how anabolic growth factors may stimulate
more than one physiologically significant event to induce
osteoblasts to progress to the final stages of differentia-
tion. Other investigators have proposed that autophagy
may be required as a checkpoint prior to entry into dif-
ferentiation because rapidly proliferating cell types re-
quire selective protein editing to eliminate errors that oc-
cur during the rapid proliferative phrase and there are
examples of anabolic growth factors stimulating au-
tophagy under these conditions (39). Additional reports
have emphasized the role of metabolic reprogramming
plays in differentiation and both AMP kinase and au-
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tophagy inductionhavebeendirectly linked to this process
during myofibroblast differentiation (40). Further study
should be directed toward defining the role of IGF-I/
IGFBP-2 in stimulating these catabolic events and why
they are necessary prior to entry into the final anabolic
stage. Although trophic factors such as IGF-I have impor-
tant role in the final stages of osteoblasts differentiation
including calcification and matrix protein synthesis, the
necessity for undergoing catabolism prior to initiation
these anabolic events and the roles played by IGF-I/
IGFBP-2 in regulating these processes requires further
investigation.
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